These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 27875375)

  • 1. Management of venous thromboembolism in myeloproliferative neoplasms.
    Barbui T; De Stefano V
    Curr Opin Hematol; 2017 Mar; 24(2):108-114. PubMed ID: 27875375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antithrombotic therapy for venous thromboembolism in myeloproliferative neoplasms.
    De Stefano V; Finazzi G; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):65. PubMed ID: 29946112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review of antithrombotic treatment of venous thromboembolism in patients with myeloproliferative neoplasms.
    Hamulyák EN; Daams JG; Leebeek FWG; Biemond BJ; Te Boekhorst PAW; Middeldorp S; Lauw MN
    Blood Adv; 2021 Jan; 5(1):113-121. PubMed ID: 33570633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists.
    De Stefano V; Ruggeri M; Cervantes F; Alvarez-Larrán A; Iurlo A; Randi ML; Elli E; Finazzi MC; Finazzi G; Zetterberg E; Vianelli N; Gaidano G; Rossi E; Betti S; Nichele I; Cattaneo D; Palova M; Ellis MH; Cacciola R; Tieghi A; Hernandez-Boluda JC; Pungolino E; Specchia G; Rapezzi D; Forcina A; Musolino C; Carobbio A; Griesshammer M; Sant'Antonio E; Vannucchi AM; Barbui T
    Leukemia; 2016 Oct; 30(10):2032-2038. PubMed ID: 27113812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
    Koschmieder S
    Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
    Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
    Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
    Arachchillage DR; Laffan M
    Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation.
    Wille K; Sadjadian P; Becker T; Kolatzki V; Horstmann A; Fuchs C; Griesshammer M
    Ann Hematol; 2019 Jan; 98(1):93-100. PubMed ID: 30155552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
    How J; Story C; Connors JM
    Postgrad Med; 2021 Jun; 133(5):508-516. PubMed ID: 33480813
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Venous thromboembolism in patients with essential thrombocythemia and polycythemia vera.
    Reikvam H; Tiu RV
    Leukemia; 2012 Apr; 26(4):563-71. PubMed ID: 22076463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
    Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
    Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases.
    De Stefano V; Rossi E; Carobbio A; Ghirardi A; Betti S; Finazzi G; Vannucchi AM; Barbui T
    Blood Cancer J; 2018 Nov; 8(11):112. PubMed ID: 30420642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018.
    Finazzi G; De Stefano V; Barbui T
    Blood Cancer J; 2018 Jun; 8(7):64. PubMed ID: 29946154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review.
    Baysal M; Bayrak M; Eşkazan AE
    Expert Rev Hematol; 2023 Feb; 16(2):131-140. PubMed ID: 36709432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.
    Mahé K; Delluc A; Chauveau A; Castellant P; Mottier D; Dalbies F; Berthou C; Guillerm G; Lippert E; Ianotto JC
    Ann Hematol; 2018 Jan; 97(1):101-107. PubMed ID: 29164292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19.
    Barbui T; De Stefano V; Alvarez-Larran A; Iurlo A; Masciulli A; Carobbio A; Ghirardi A; Ferrari A; Cancelli V; Elli EM; Andrade-Campos MM; Kabat MG; Kiladjian JJ; Palandri F; Benevolo G; Garcia-Gutierrez V; Fox ML; Foncillas MA; Morcillo CM; Rumi E; Osorio S; Papadopoulos P; Bonifacio M; Cervantes KSQ; Serrano MS; Carreno-Tarragona G; Sobas MA; Lunghi F; Patriarca A; Elorza BN; Angona A; Mazo EM; Koschmieder S; Carli G; Cuevas B; Hernandez-Boluda JC; Abadia EL; Cirici BX; Guglielmelli P; Garrote M; Cattaneo D; Daffini R; Cavalca F; Bellosillo B; Benajiba L; Curto-Garcia N; Bellini M; Betti S; Harrison C; Rambaldi A; Vannucchi AM
    Blood Cancer J; 2021 Feb; 11(2):21. PubMed ID: 33563901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolism prophylaxis in patients with Philadelphia-negative myeloproliferative neoplasms-Clinical practice among Nordic specialists.
    Bjerrum OW; Samuelsson J; Ghanima W; Kauppila M; Andersen CL;
    Eur J Haematol; 2018 May; 100(5):475-478. PubMed ID: 29427461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asian venous thromboembolism guidelines: updated recommendations for the prevention of venous thromboembolism.
    Liew NC; Alemany GV; Angchaisuksiri P; Bang SM; Choi G; DE Silva DA; Hong JM; Lee L; Li YJ; Rajamoney GN; Suviraj J; Tan TC; Tse E; Teo LT; Visperas J; Wong RS; Lee LH
    Int Angiol; 2017 Feb; 36(1):1-20. PubMed ID: 27606807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry.
    Barillari G; Londero AP; Brenner B; Nauffal D; Muñoz-Torrero JF; Del Molino F; Moustafa F; Madridano O; Martín-Martos F; Monreal M;
    Eur J Intern Med; 2016 Jul; 32():53-9. PubMed ID: 26972931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.